Pharmacogenomics Market is Expected to Reach $5.8 Billion | MarketsandMarkets™

Chicago, March 04, 2024 (GLOBE NEWSWIRE) — Pharmacogenomics market in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $5.8 billion by 2028, growing at a CAGR of 10.6% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. Factors like increasing incidences of chronic diseases, rising cancer research activities, and growing investments and fundings in the field of genomics are driving the growth of pharmacogenomics market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142682251

Pharmacogenomics Market Scope:

Report Coverage Details
Market Revenue in 2023 $3.5 billion
Estimated Value by 2028 $5.8 billion
Growth Rate Poised to grow at a CAGR of 10.6%
Market Size Available for 2021–2028
Forecast Period 2023–2028
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Product & Service, Technology, Disease Area, Application, and End User
Geographies Covered North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
Report Highlights Updated financial information / product portfolio of players
Key Market Opportunity Utilization of genomics in personalized medicine
Key Market Driver Growing prevalence of chronic and genetic diseases

Advancements in pharmacogenomics, driven by breakthroughs in DNA sequencing and data analytics, are revolutionizing drug development and personalizing patient treatment. Precision medicine platforms leverage genetic information to tailor drug therapies, minimizing adverse reactions and optimizing efficacy. This transformative shift in healthcare is reshaping the pharmaceutical industry, fostering a more targeted and efficient approach to drug discovery and delivery.

Based on product & service, the pharmacogenomics market is segmented into kits & reagents and service. Kits & reagents accounted for the largest share of the global pharmacogenomics market in 2022. The kits & reagents segment is further categorized as sequencing kits & reagents, PCR sequencing kits & reagents, microarray sequencing kits & reagents, and other sequencing kits & reagents. The large share of this segment can primarily be attributed the advantages associated with kits & reagents, such as ultra-high-throughput, scalability, and high speed, enable researchers to perform a wide range of applications, more comprehensive, and cost and time effective.

Based on technology, the pharmacogenomics market is segmented into sequencing, PCR, microarray, and other technologies. In 2022, sequencing accounted for the largest share of the pharmacogenomics market. The large share of this segment can be attributed to the high adoption of sequencing in personalized medicine, human genomics, heightened genomics research. Additionally, increased availability of funds, investments, and grants, are anticipated to propel the market for sequencing technology in the forecast period.

Based on diseases area, the pharmacogenomics market is segmented into cancer, cardiovascular, neurological diseases, and other diseases. In 2022, cancer accounted for largest share of the pharmacogenomics market due to increasing prevalence of cancer. Moreover, growing cancer research activities are expected to drive the demand for segment during the forecast period.
Based on application, the pharmacogenomics market has been segmented into personalized medicine, clinical research, and drug discovery & preclinical development. In 2022, personalized medicine accounted for the largest market share owing to increasing demand for advanced drug products for the treatment of chronic and genetic diseases.

Based on end user, the pharmacogenomics market has been segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2022, academic & research institutes accounted for the largest share of the pharmacogenomics market. The growing research activities, supported by rising fundings for research drives the growth of pharmacogenomics market among academic and research institutes.

The key regional markets for the global pharmacogenomics market are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the market. The large share of this region can be attributed to the increasing research funding and government initiatives for promoting precision medicine and the presence of leading pharmacogenomic product and service providers in the region. However, during the forecast period, the Asia Pacific is expected to be the fastest-growing regional market. Factors such as the increasing research activities in the field of genomics and increasing research fundings and investments by pharmaceutical and biotechnology companies for the advancement of the healthcare sector are projected to drive the growth of pharmacogenomics market in Asia Pacific.

Buy a Pharmacogenomics Industry Report (396 Pages PDF with Insightful Charts, Tables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=142682251

Pharmacogenomics market major players covered in the report, such as:

  • Illumina, Inc. (US)
  • Thermo Fisher Scientific Inc. (US)
  • Danaher Corporation (US)
  • Laboratory Corporation of America Holdings (US)
  • Charles River Laboratories (US)
  • Eurofins Scientific (Luxembourg)
  • Bio-Rad Laboratories, Inc. (US)
  • Agilent Technologies, Inc. (US)
  • BD (US)
  • QIAGEN (Netherlands)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Revvity (US)
  • IQVIA Inc. (US)
  • Mesa Labs, Inc. (US)
  • Medpace (US)
  • MGI Tech Co., Ltd. (China)
  • Takara Bio Inc. (Japan)
  • PacBio (US)
  • New England Biolabs (US)
  • BGI (China)
  • Novogene Co., Ltd. (China)
  • SOPHiA GENETICS (Switzerland)
  • Fios Genomics (UK)
  • Personalis, Inc. (US)
  • BioAI Health Inc. (US)
  • NeoGenomics Laboratories (US)
  • Macrogen, Inc. (South Korea)
  • and Among Others

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=142682251

This report categorizes the pharmacogenomics market into the following segments:

Pharmacogenomics Market, by Product & Service

  • Kits & Reagents
    • Sequencing Kits and Reagents
    • PCR Kits and Reagents
    • Microarray Kits and Reagents
    • Other Kits and Reagents
  • Service

Pharmacogenomics Market, by Technology

  • Sequencing
  • PCR
  • Microarray
  • Other Technologies

Pharmacogenomics Market, by Disease Area

  • Cancer
  • Cardiovascular
  • Neurological Diseases
  • Other Disease Areas

Pharmacogenomics Market, by Application

  • Personalized Medicine
  • Clinical Research
  • Drug discovery & Preclinical Development

Pharmacogenomics Market, by End User

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations

Pharmacogenomics Market, by region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America (RoLATAM)
  • Middle East & Africa
    • Middle East
      • GCC
      • Rest of Middle East (RoME)
    • Africa

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=142682251

Key Market Stakeholders:

  • Academic & Research Institutes
  • Biotechnology Companies
  • Pharmaceutical & Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Genomics Product & Service Providers
  • Market Research & Consulting Firms
  • Venture Capitalists & Investors
  • Government Associations
  • Manufacturers of Pharmacogenomics Testing Products

Report Objectives:

  • To define, describe, and forecast the global pharmacogenomics market based on product & service, technology, application, disease area, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the global pharmacogenomics market and comprehensively analyze their core competencies2 and market shares
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the pharmacogenomics market
  • To benchmark players in the pharmacogenomics market using the “Company Evaluation Matrix” framework, which analyzes market players based on various parameters, including product portfolio, geographic reach, and market share

Related Reports:

Microbiome Diagnostics Market

Epigenetics Market

Sterility Testing Market

Blood Group Typing Market

Metagenomic Sequencing Market

Research Insights: https://www.marketsandmarkets.com/ResearchInsight/pharmacogenomics-market.asp

Content Source: https://www.marketsandmarkets.com/PressReleases/pharmacogenomics.asp

CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy